{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:01:41Z","timestamp":1790492501000,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Holding SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:37:37Z","timestamp":1780119457000},"page":"652-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus"],"prefix":"10.1016","volume":"9","author":[{"given":"Paolo","family":"Gontero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Bridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane Dalila","family":"Delattre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Vosgerau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Wyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medi","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.05.007_b0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.007_b0010","unstructured":"Gontero P, Baard J, Birtle A, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Accessed March 26, 2026. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf."},{"key":"10.1016\/j.euo.2026.05.007_b0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4111\/icu.20230042","article-title":"Treatment strategies for the Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"64","author":"Jeong","year":"2023","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euo.2026.05.007_b0020","unstructured":"Chun D, Broughton E, Gooden K, Mycock K, Rajkovic I, Taylor-Stokes G. Reasons for non-surgical management of patients with Bacillus Calmette\u2013Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC); 2020."},{"key":"10.1016\/j.euo.2026.05.007_b0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.05.007_b0030","unstructured":"European Medicines Agency. Reflection paper on establishing efficacy based on single arm trials submitted as pivotal evidence in a marketing authorisation \u2013 considerations on evidence from single-arm trials. Updated 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-establishing-efficacy-based-single-arm-trials-submitted-pivotal-evidence-marketing-authorisation-application_en.pdf."},{"key":"10.1016\/j.euo.2026.05.007_b0035","unstructured":"Food and Drug Administration. Summary Basis for Regulatory Action \u2013 nadofaragene firadenovec-vncg (ADSTILADRIN). Updated 2022. https:\/\/www.fda.gov\/media\/164532\/download?attachment."},{"key":"10.1016\/j.euo.2026.05.007_b0040","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.05.007_b0045","unstructured":"Urology Times. Nogapendekin Alfa Inbakicept receives EU authorization for BCG-unresponsive NMIBC. Updated 2026. https:\/\/www.urologytimes.com\/view\/nogapendekin-alfa-inbakicept-receives-eu-authorization-for-bcg-unresponsive-nmibc."},{"key":"10.1016\/j.euo.2026.05.007_b0050","unstructured":"European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP). 2026. Updated March 27, 2026. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2026."},{"key":"10.1016\/j.euo.2026.05.007_b0055","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the society for immunotherapy of cancer and the international bladder cancer group","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.05.007_b0060","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eururo.2024.08.001","article-title":"Bladder-sparing therapy for Bacillus Calmette-Gu\u00e9rin\u2013unresponsive non\u2013muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection","volume":"86","author":"Li","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.007_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008508","article-title":"Toward standardization in bladder cancer clinical trials: guidance from the SITC-IBCG expert panel","volume":"12","author":"Myers","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2026.05.007_b0070","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.05.007_b0075","unstructured":"National Comprehensive Cancer Network. Bladder cancer \u2013 NCCN evidence blocks. version 1.2026; Updated 2026."},{"key":"10.1016\/j.euo.2026.05.007_b0080","article-title":"New treatment options for non-muscle-invasive bladder cancer","volume":"45","author":"Filon","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:43:16Z","timestamp":1783197796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2588931126001343"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.05.007","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}